ReviewBrain research2013
New tricks for old dogmas: optogenetic and designer receptor insights for Parkinson's disease.
Review in Brain research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Characterization of Ultrapotent Chemogenetic Ligands for Research Applications in Nonhuman Primates.ACS chemical neuroscience · 2022Article
- New Targets and New Technologies in the Treatment of Parkinson's Disease: A Narrative Review.International journal of environmental research and public health · 2022Review
- Chemogenetic silencing of the midline and intralaminar thalamus blocks amygdala-kindled seizures.Experimental neurology · 2016Article
- Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.Journal of neurophysiology · 2016Review
- Optogenetic Approaches to Target Specific Neural Circuits in Post-stroke Recovery.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2016Review
- Nutritional and Nanotechnological Modulators of Microglia.Frontiers in immunology · 2016Review
- Neuroprotective Transcription Factors in Animal Models of Parkinson Disease.Neural plasticity · 2016Review
- Treating Parkinson's disease in the 21st century: can stem cell transplantation compete?The Journal of comparative neurology · 2014Review
- Designer receptors: therapeutic adjuncts to cell replacement therapy in Parkinson's disease.The Journal of clinical investigation · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Optogenetics and novel designer receptors have revolutionized the way neuroscientists can interrogate neural circuits. These new tools are being rapidly applied to many facets of neuroscience including the study of Parkinson's disease circuitry and therapies. This review highlights how optogenetics and designer receptors can be applied in the study of Parkinsonian dysfunction to understand the mechanisms behind motor and non-motor symptoms. We discuss how these tools have recently advanced our understanding of basal ganglia function and outline how they can be applied in future to refine existing treatments and generate novel therapeutic strategies for Parkinson's disease. This article is part of a Special Issue entitled Optogenetics (7th BRES).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.